Clinical trial
Sildenafil Citrate for the Treatment of Established Pre-Eclampsia
NCT00141310 · Pfizer's Upjohn has merged with Mylan to form Viatris Inc., Industry · Terminated
Key facts
| NCT number | NCT00141310 |
|---|---|
| Title | Sildenafil Citrate for the Treatment of Established Pre-Eclampsia |
| Official title | A Randomised, Double-Blind, Placebo-Controlled, Flexible-Dose, Parallel-Group Study to Evaluate the Efficacy, Safety and Toleration of Oral Sildenafil Citrate Administered in the Dose Range of 20 - 80 Mg TID for the Treatment of Pre-Eclampsia. (PET) |
| Lead sponsor | Pfizer's Upjohn has merged with Mylan to form Viatris Inc., Industry |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Pre-eclampsia |
| Intervention type | Drug |
| Interventions | Sildenafil citrate |
| Enrollment | 76 |
| Start date | Sep 1, 2004 |
| Completion | Apr 1, 2006 |
| First posted | Sep 1, 2005 |
| Last update posted | Feb 1, 2021 |
| Countries | United Kingdom |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: